News
The debate continues over the potential of measurable residual disease to transform research and clinical care in hematology.
GSK RSV vaccine Arexvy accepted for regulatory review by EMA to expand use in adults 18 years, older
London: GSK plc has announced that the European Medicines Agency (EMA) has accepted the company's regulatory application to ...
India also impacted by Shigellosis, a severe form of bacterial diarrhoea that disproportionately affects children under five ...
England’s NHS has launched a groundbreaking “Trojan Horse” therapy for the treatment of myeloma, offering hope for thousands ...
Bengaluru: In a BSE filing, Syngene International has informed that the company's facility at Semicon Park, Bengaluru has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results